TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc. (TCRR) priced its initial public offering on Feb 15, 2019 at $15.00 per share, within its $14.00–$16.00 range, raising $75M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $347.8M. Jefferies was lead-left underwriter, joined by Leerink Partners, BMO Capital Markets and Wedbush. Goodwin Procter advised the company and WilmerHale advised the underwriters.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for cancer. Its TRuC-T cells use the full T cell receptor signaling complex to recognize and kill cancer cells, without needing human leukocyte antigen matching, with a focus on solid tumors.

Status

IPO

Ticker

TCRR

Exchange

Nasdaq Global Select

Priced

Feb 15, 2019

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$75M

Market cap at IPO price

$347.8M

First filed

Dec 28, 2018

Underwriters

Jefferies, Leerink Partners, BMO Capital Markets and Wedbush

Company counsel

Goodwin Procter

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.